Pharmaceuticals | Vanta BioScience

Pharmaceutical and Biopharmaceutical product development requires a concerted effort considering the risk of failure in the drug discovery and development funnel. Current approaches also suggest that companies prefer to fail early and to fail cheap. Economy trends point to the phenomenon of fair price discovery at outsourcing destinations in Indo-China for preclinical development.

Vanta Bioscience has developed its service portfolio based primarily on OECD approved test guidelines as indicated below. With the expertise of scientific staff having more than 100 years of GLP experience and with worldwide recognized certifications (DABT), Vanta is well positioned to offer services in Toxicology and Pharmacology for clientele in the Pharmaceutical and biotech space.

General Toxicology
Study Code	Study Title	OECD TG#
GN01	Acute toxicity, single dose, rodents	423
GN02	Acute toxicity, single dose, rodents	425
GN04	Multiple dose 14 – 28 days, with recovery group	407
GN06	Multiple dose 90 days, with recovery group	408
GN08	Chronic toxicity in rodents, 6 months	452
GN09	Chronic toxicity in rodents, 12 months	452
GN012	Acute toxicity, dermal (full study)	402
GN012	Acute eye irritation in rabbit	405
GN015	Local irritancy in rabbit (skin)	404
GN016	Guinea pig maximization (Magnusson-Kligman)	406
GN017	Mouse ear swelling test	–
GN018	Phototoxicity test in mouse	432
CG01	Chronic toxicity 18 months in mouse	451
CG02	Chronic toxicity 2 years in rodents	453

Developmental & Reproductive Toxicology
Study Code	Study Title	OECD TG#
RT01	Fertility, reproductive performance & early embryonic development (Seg. I)	414
RT02	Embryo fetal development (birth defects and embryo toxicity) teratology (Seg. II)	415
RT03	Pre and post natal Development (Seg. III)	416

Genotoxicity
Study Code	Study Title	OECD TG#
GT01	Ames assay, in vitro	471
GT02	Chromosomal aberration, in vitro	473
GT03	Chromosomal aberration, in vivo	475
GT04	Micronucleus in vivo	474